Abstract
Gastric cancer represents a challenging health problem around the world. It is the fourth most common cancer behind lung, breast, and colon and rectum cancers. An analysis of the worldwide incidence and mortality from gastric cancer had estimated that 691,432 new cases among men and 375,111 cases among women would occur in 2007 (Garcia et al. 2007). It was also estimated that approximately 800,000 patients would die of this disease annually (Garcia et al. 2007). In the United States, it was estimated that 21,000 new cases of gastric cancer would occur in 2010, with 10,570 deaths expected (Jemal et al. 2010).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ajani JA, Crane CH, Wu TT et al (2005) Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol 23:1237
Ajani JA, Fairweather J, Dumas P et al (1998) Phase II study of Taxol in patients with advanced untreated gastric carcinoma. Cancer J Sci Am 4(4):269–274
Ajani JA, Mansfield PF, Janjan N et al (2004a) Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol 22:2774
Ajani JA, Walsh G, Komaki R et al (2004b) Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Cancer 100:2347
Ajani JA, Winter K, Okawara GS et al (2006) Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol 24:3953
Allal AS, Swahlen D, Bründler MA et al (2005) Neoadjuvant radiochemotherapy for locally advanced gastric cancer: long-term results of a phase I trial. Int J Radiat Oncol Biol Phys 63:1286
Baker J, Ajani JA, Ho L et al (2001) CPT-11 plus cisplatin as second line therapy of advanced gastric or GE junction adenocarcinoma (AGC-AGEJC). Proc Am Soc Clin Oncol 20(suppl):A647
Bang YJ, Van Cutsem E, Chung H et al. (2010) Trastuzumab in combination with chemotherapy alone for the treatment of HER2 positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase III open label randomized control trial. The Lancet 376:687–697
Berlin J, Washington M (2006) Uncommon cancers of the stomach. In: Raghavan D, Blecher M, Johnson D (eds) Textbook of uncommon cancer, 3rd edn. Wiley, Chichester, England, pp 352–366
Besa P, Garrido M, Bustos M et al (2006) Adjuvant chemoradiotherapy for gastric adenocarcinoma, toxicity, survival, and prognostic factors. Int J Radiat Oncol Biol Phys 66:262
Blair V, Martin I, Shaw D et al (2006) Hereditary diffuse gastric cancer diagnosis and management. Clin Gastroenterol Hepatol 4(3):262–275
Blanke CD, Haller DG, Benson AB et al (2001) A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma. Ann Oncol 12(11):1575–1580
Bleiberg H, Goffin JC, Dalesio O et al (1989) Adjuvant radiotherapy and chemotherapy in resectable gastric cancer: a randomized trial of the gastrointestinal tract cancer cooperative group of the EORTC. Eur J Surg Oncol 15:535
Bollschweiler E, Boettcher K, Hoelscher AH, Sasako M, Kinoshita T, Maruyama K et al (1992) Preoperative assessment of lymph node metastases in patients with gastric cancer: evaluation of the Maruyama computer program. Br J Surg 79(2):156–160
Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ; Dutch Gastric Cancer Group (1999) Extended lymph-node dissection for gastric cancer. N Engl J Med 340(12):908–914
Bonenkamp JJ, Songun I, Hermans J, Sasako M, Welvaart K, Plukker JT et al (1995) Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 345(8952):745–748
Bouche O, Raoul JL, Giovanini M et al (2003) Randomized phase II trial of LV5-FU2, LV5-FU2-cisplatinum or LV5-FU2-irinotecan in patients with metastatic gastric or cardial adenocarcinoma: final results of study FFCD 9803. Proc Am Soc Clin Oncol 21(suppl):A1033
Bozzetti F, Marubini E, Bonfanti G, Miceli R, Piano C, Crose N et al; The Italian Gastrointestinal Tumor Study Group (1997) Total versus subtotal gastrectomy: surgical morbidity and mortality rates in a multicenter Italian randomized trial. Ann Surg 226(5):613–620
Bozzetti F, Marubini E, Bonfanti G, Miceli R, Piano C, Gennari L; Italian Gastrointestinal Tumor Study Group (1999) Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Ann Surg 230(2):170–178
Bozzetti F, Bonfanti G, Bufalino R, Menotti V, Persano S, Andreola S et al (1982) Adequacy of margins of resection in gastrectomy for cancer. Ann Surg 196(6):685–690
Cascinu S, Scartozzi M, Labiance R et al (2004) High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgrastim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Br J Cancer 90:1521
Childs DS Jr, Moertel CG, Holbrook MA et al (1968) Treatment of unresectable adenocarcinoma of the stomach with a combination of 5-fluorouracil and radiation. Am J Roentgenol 102:541
Coburn N, Govindarajan A, Law C et al (2007) State-specific effect of adjuvant therapy following gastric cancer resection: a population-based analysis of 4,041 patients. Ann Surg Oncol: Springer Science + Business Media, L.L.C. volume 15:500–507
Cullinan SA, Moertel CG, Fleming TR et al (1985) A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA 253(14):2061–2067
Cullinan SA, Moertel CG, Wieand HS et al (1994) Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. J Clin Oncol 12(2):412–416
Cunningham D, Cahn A, Menzies-Gow N (1990) Cisplatin, epirubicin and 5-flourouracil (CEF) has significant activity in advanced gastric cancer. Proc Am Soc Clin Oncol 9:123
Cunningham D, Allum WH, Stenning SP et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11–20
Cuschieri A, Fayers P, Fielding J, Craven J, Bancewicz J, Joypaul V et al (1996) Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet 347(9007):995–999
Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V et al (1999) Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 79(9–10):1522–1530
Dank M, Zaluski J, Barone C et al (2005) Randomized phase 3 trial of irinotecan (CPT-11) + 5-FU/folinic acid (FA) vs. CDDP + 5-FU in 1st line advanced gastric cancer patients. Proc Am Soc Clin Oncol 23(suppl):A4003
Degiuli M, Sasako M, Ponti A, Soldati T, Danese F, Calvo F (1998) Morbidity and mortality after D2 gastrectomy for gastric cancer: results of the Italian Gastric Cancer Study Group prospective multicenter surgical study. J Clin Oncol 16(4):1490–1493
Dent DM, Werner ID, Novis B et al (1979) Prospective randomized trial of combined oncological therapy for gastric carcinoma. Cancer 44(2):385–391
Dooley CP, Larson AN, Stace NA etal (1984) Double contrast barium meal and upper gastrointestinal endoscopy. Ann Intern Med 101: 538
Douglass HO Jr, Lavin PT, Goudsmit A et al (1984) An Eastern Cooperative Oncology Group evaluation of combinations of methyl-CCNU, mitomycin-C, Adriamycin, and 5-fluorouracil in advanced measurable gastric canter (EST 2277). J Clin Oncol 2(12):1372–1381
Earle CC, Maroun JA (1999) Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 35(7):1059–1064
Fiorica F, Cartei F, Enea M et al (2007) The impact of radiotherapy on survival in resectable gastric carcinoma: a meta-analysis of literature data. Cancer Treat Rev 33:729
Gallardo-Rincón D, Oñate-Ocaña LF, Calderillo-Ruiz G (2000) Neoadjuvant chemotherapy with P-ELF (cisplatin, etoposide, leucovorin, 5-fluorouracil) followed by radical resection in patients with initially unresectable gastric adenocarcinoma: a phase II study. Ann Surg Oncol 7:45
Garcia M, Jemal A, Ward EM, Center MM, Hao Y, Siegel RL, Thun MJ (2007) Global cancer facts & figures 2007. American Cancer Society, Atlanta, GA
Glimelius B, Ekstrom K, Hoffman K et al (1977) Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8(2):163–168
Gotoda T, Yanagisawa A, Sasako M, Ono H, Nakanishi Y, Shimoda T et al (2000) Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gastric Cancer 3(4):219–225
Gouzi JL, Huguier M, Fagniez PL, Launois B, Flamant Y, Lacaine F et al (1989) Total versus subtotal gastrectomy for adenocarcinoma of the gastric antrum. A French prospective controlled study. Ann Surg 209(2):162–166
Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG et al (eds) (2002) AJCC cancer staging manual. Springer, New York
Guadagni S, de Manzoni G, Catarci M, Valenti M, Amicucci G, De Bernardinis G et al (2000) Evaluation of the Maruyama computer program accuracy for preoperative estimation of lymph node metastases from gastric cancer. World J Surg 24(12):1550–1558
Gunderson LL (2002) Gastric cancer – patterns of relapse after surgical resection. Semin Radiat Oncol 12:150
Gunderson LL, Sosin H (1982) Adenocarcinoma of the stomach: areas of failure in a reoperation series (second or symptomatic looks) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 8:1
Haas CD, Mansfield CM, Leichman LP et al (1983) Combined nonsimultaneous radiation therapy and chemotherapy with 5-FU, doxorubicin, and mitomycin for residual localized gastric adenocarcinoma: A Southwest Oncology Group pilot study. Cancer Treat Rep 67:421
Hallissey MT, Dunn JA, Ward LC et al (1994) Adjuvant chemotherapy in operable gastric cancer: 5-year follow-up of first British Stomach Cancer Group trial. Lancet 343:1309
Hartgrink HH, Van De Velde CJ, Putter H, Bonenkamp JJ, Klein Kranenbarg E, Songun I et al (2004) Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 22:2069–2077
Hashimoto K, Mayahara H, Takashima A et al (2009) Palliative radiation therapy for hemorrhage of unresectable gastric cancer: a single institute experience. J Cancer Res Clin Oncol 135(8):1117–1123
Hawkins R, Cunningham D, Soerbye H et al (2003) Randomized phase II trial of docetaxel plus irinotecan versus docetaxel plus 5-fluorouracil in patients with untreated advanced gastric adenocarcinoma. Am Soc Clin Oncol 22(suppl):A1032
Hiki Y (1996) Endoscopic mucosal resection (EMR) for early gastric cancer. Nippon Geka Gakkai Zasshi 97(4):273–278
Hofman M, Stoss, O Shi D et al. (2008) Assessment of a HER2 scoring system for gastric cancer. Results from avalidation study. Histopathology 52: 797–805
Holbrook MA (1974) Radiation therapy: current concepts in cancer. Gastric cancer: treatment principles. JAMA 228:1289
Horn RC (1955) Carcinoma of the stomach: autopsy findings in untreated cases. Gastroenterology 29:515
Hundahl SA (2005) Evidence-based recommendations for local-regional control of gastric cancer. Cancer Invest 23(4):352–362
Hundahl SA, Macdonald JS, Benedetti J, Fitzsimmons T (2002) Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: the effect of undertreatment. Ann Surg Oncol 9(3):278–286
Hundahl SA, Macdonald JS, Benedetti J (2004) Durable survival impact of “Low Maruyama Index Surgery” in a trial of adjuvant chemoradiation for gastric cancer. 2004 ASCO GI Symposium, San Francisco, 22 January 2004. Report No.: 48
Hundahl S, Macdonald J, Smalley S (2006) Stomach. In: Chang A, Ganz P, Hayes D et al (eds) Oncology: an evidence-based approach. Springer, New York, p 680–703
Ilson D, Enzinger P, Saltz L et al (1999a) Phase II trial of weekly irinotecan + cisplatin in advanced gastric cancer. Proc Am Soc Clin Oncol 18(suppl):A994
Ilson DH, Saltz L, Enzinger P et al (1999b) Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 17(10):3270–3275
Jamieson GG, Gill PG (1981) A prospective trial of 5-FU and BCNU in the treatment of advanced gastric cancer. Aust N Z J Surg 51(1):16–19
Jansen E, Boot H, Verheij M et al (2005) Optimal locoregional treatment in gastric cancer. J Clin Oncol 23:4509
(1995) Japanese classification of gastric carcinoma, first English edition. Kanehara company, Tokyo
Japanese Gastric Cancer Association (1998) Japanese classification of gastric carcinoma – 2nd English edition. Gastric Cancer 1(1):10–24
Jemal A, Siegel R, Xu J, Ward E (2010) Cancer Statistics 2010. CA A Cancer Journal for Clinicians; 60:277–300
Kajitani T (1981) The general rules for the gastric cancer study in surgery and pathology. Part I. Clinical classification. Jpn J Surg 11(2):127–139
Kampschoer GH, Maruyama K, van de Velde CJ, Sasako M, Kinoshita T, Okabayashi K (1989) Computer analysis in making preoperative decisions: a rational approach to lymph node dissection in gastric cancer patients. Br J Surg 76(9):905–908
Kasakura Y, Fujii M, Mochizuki F, Kochi M, Kaiga T (2000) Is there a benefit of pancreaticosplenectomy with gastrectomy for advanced gastric cancer? Am J Surg 179(3):237–242
Kassam Z, MacKay H, Buckley C et al (2005) Quality of life during adjuvant chemoradiation for gastric adenocarcinoma. Int J Radiat Oncol Biol Phys 72:2193
Kaurah P, Huntsman D (2004) Hereditary diffuse gastric cancer. University of Washington, Seattle. http://www.genetests.org. Accessed 1 July 2006
Kelsen D, Atiq OT, Saltz L et al (1991) FAMTX (fluorouracil, methotrexate, Adriamycin) is as effective and less toxic than EAP (etoposide, Adriamycin, cisplatin): a random assignment trial in gastric cancer. Proc Am Soc Clin Oncol 10:137
Kim S, Lim DH, Lee J et al (2005) An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys 63:1279
Kim MM, Mansfield PF, Das P et al (2008a) Chemoradiation therapy for potentially resectable gastric cancer: clinical outcomes among patients who do not undergo planned surgery. Int J Radiat Oncol Biol Phys 71:167
Kim MM, Rana V, Janjan NA et al (2008b) Clinical benefit of palliative radiation therapy in advanced gastric cancer. Acta Oncol 47:421
Kingston RD, Ellis DJ, Powell J et al (1978) The West Midlands gastric carcinoma chemotherapy trial: planning and results. Clin Oncol 4(1):55–69
Klein HO, Dias Wickramanayake P, Dieterle F (1982) Chemotherapieprotokoll zur behandlung des metasierenden magenkarzinos: methotrexat, Adriamycin, 5-fluorouracil. Dtsch Med Wochenschr 107:1708–1715
Kobayashi T, Kazui T, Kimura T (2003) Surgical local resection for early gastric cancer. Surg Laparosc Endosc Percutan Tech 13(5):299–303
Kobayashi T, Gotohda T, Tamakawa K, Ueda H, Kakizoe T (2004) Magnetic anchor for more effective endoscopic mucosal resection. Jpn J Clin Oncol 34(3):118–123
Kovach JS, Moertel CG, Schutt AJ et al (1974) A controlled study of combined 1, 3-bis-(2-chlorethyl)-1-nitrosourea and 5-fluorouracil therapy for advanced gastric and pancreatic cancer. Cancer 33(2):563–569
Kozak KR, Moody JS (2008) The survival impact of the Intergroup 0116 trial on patients with gastric cancer. Int J Radiat Oncol Biol Phys 72:517
Kuwano H, Mochiki E, Asao T, Kato H, Shimura T, Tsutsumi S (2004) Double endoscopic intraluminal operation for upper digestive tract diseases: proposal of a novel procedure. Ann Surg 239(1):22–27
Landry J, Tepper JE, Wood WC et al (1990) Analysis of survival and local control following surgery for gastric cancer. Int J Radiat Oncol Biol Phys 191:1357
Lowy AM, Feig BW, Janjan N et al (2001) A pilot study of preoperative chemoradiotherapy for resectable gastric cancer. Ann Surg Oncol 8:519
Macdonald J, Hill M, Roberts (1992) Gastric cancer: epidemiology, pathology, detection and staging. In: Ahlgren J, Macdonald J (eds) Gastrointestinal oncology. Lippincott, Philadelphia, PA, pp 151–158
Macdonald JS, Smalley SR, Benedetti J et al (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725–730
Macdonald JS, Smalley SR, Benedetti J et al (2009) Chemoradiation of resected gastric cancer: a 10-year follow-up of the phase III trial INT0116 (SWOG 9008). Jour Clin Oncol. 27:15a Abstract 4515
Manson S (2006) Mucosa-associated lymphoid tissue (MALT) lymphoma. Semin Oncol Nurs 22(2):73–79
Mari E, Floriani I, Tinazzi A et al (2000) Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials: a study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente). Ann Oncol 11: 837–843
Maruyama K, Sasako M, Kinoshita T, Sano T, Katai H, Okajima K (1995) Pancreas-preserving total gastrectomy for proximal gastric cancer. World J Surg 19(4):532–536
Mattioli S, Di Simone MP, Ferruzzi L et al (2001) Surgical therapy for adenocarcinoma of the cardia: modalities of recurrence and extension of resection. Dis Esophagus 14:104
McNeer G, Vandenberg H, Dong FY et al (1957) A critical evaluation of subtotal gastrectomy for the cure of cancer of the stomach. Ann Surg 134:2
Melcher AA, Mort D, Maughan TS (1996) Epirubicin, cisplatin, and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastroesophageal cancer. Br J Cancer 74:1651
Menges M, Schmidt C, Lindemann W et al (2003) Low toxic neoadjuvant cisplatin, 5-fluorouracil, and folinic acid in locally advanced gastric cancer yields high R-0 resection rate. J Cancer Res Clin Oncol 129:423
Moehler MH, Siebler J, Hoehler T et al (2003) Safety and efficacy of CPT11/FA/5-FU (ILF) versus ELF in previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. Proc Am Soc Clin Oncol 22(suppl):A1034
Moertel CG (1976) Chemotherapy of gastrointestinal cancer. Clin Gastroenterol 5(3):777–793
Moertel CG, Lavin PT (1979) Phase II–III chemotherapy studies in advanced gastric cancer. Cancer Treat Rep 63(11–12):1863–1869
Moertel CG, Childs DS Jr, Reitemeier RJ et al (1964) Combined 5-fluorouracil and supervoltage radiation therapy in the palliative management of advanced gastrointestinal cancer: a pilot study. Mayo Clin Proc 39:767
Moertel CG, Childs DS Jr, Reitemeier RJ et al (1969) Adjuvant radiotherapy or chemotherapy in resectable gastric cancer: 5-year follow-up of second British Stomach Cancer Group trial. Lancet 2:865
Moertel CG, Rubin J, O’Connell MJ et al (1986) A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. J Clin Oncol 4(7):1053–1057
Moiseyenko VM, Van Cutsem E, Tjulandin S et al (2002) Docetaxel-cisplatin-5-FU (CD) versus cisplatin-5-FU (CF) as first line therapy for gastric cancer: interim analysis results on efficacy and safety in a multicenter randomized phase III study. Proc Am Soc Clin Oncol 21(suppl 1):A587
Murad AM, Santiago FF, Petroianu A et al (1993) Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72(1):37–41
Newman E, Mulholland M (2006) Prophylactic gastrectomy for hereditary diffuse gastric cancer syndrome. J Am Coll Surg 202(4):612–617
Ono H, Kondo H, Gotoda T, Shirao K, Yamaguchi H, Saito D et al (2001) Endoscopic mucosal resection for treatment of early gastric cancer. Gut 48(2):225–229
Park JO, Chung HC, Cho JY et al (1997) Retrospective comparison of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (modified FAM) combination chemotherapy versus palliative therapy in treatment of advanced gastric cancer. Am J Clin Oncol 20(5):484–489
Parkin D, Bray F, Ferlay J, Pisani D (2005) Global cancer statistics, 2002. CA: Cancer J Clin 55:74–108
Pathirana A, Poston GJ (2001) Lessons from Japan – endoscopic management of early gastric and oesophageal cancer. Eur J Surg Oncol 27(1):9–16
Peeters KCMJ, Hundahl SA, Kranenbarg EK, Hartgrink H, vandeVelde CJH (2005) “Low-Maruyama-Index” surgery for gastric cancer – a blinded re-analysis of the Dutch D1-D2 trial. World J Surg 29:1576–1584
Preusser P, Wilke H, Achterrath W et al (1989) Phase II study with combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 7(9):1310–1317
Pyrhonen S, Kuitunen T, Nyandoto P et al (1995) Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71(3):587–591
Rake MO, Mallinson CN, Cocking JB et al (1976) Assessment of the value of cytotoxic therapy in the treatment of carcinoma of the stomach. Gut 17:832
Reed VK, Krishnan S, Mansfield PF et al (2008) Incidence, natural history, and patterns of locoregional recurrence in gastric cancer patients treated with preoperative chemoradiotherapy. Int J Radiat Oncol Biol Phys 71:741
Robertson CS, Chung SC, Woods SD, Griffin SM, Raimes SA, Lau JT et al (1994) A prospective randomized trial comparing R1 subtotal gastrectomy with R3 total gastrectomy for antral cancer. Ann Surg 220(2):176–182
Roth AD, Fazio N, Stupp R et al (2007) Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol 25(22):3217–3223
Safran H, Wanebo HJ, Hesketh PJ et al (2000) Paclitaxel and concurrent radiation for gastric cancer. Int J Radiat Oncol Biol Phys 46:889
Saikawa Y, Kubota T, Kumagai K et al (2008) Phase II study of chemoradiotherapy with S-1 and low-dose cisplatin for inoperable advanced gastric cancer. Int J Radiat Oncol Biol Phys 71:173
Sakuramoto S, Sasako M, Yamaguchi T et al (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810–1820
Sano T, Katai H, Sasako M, Maruyama K (2000) The management of early gastric cancer. Surg Oncol 9(1):17–22
Sasako M (1997) Treatment of early gastric cancer. Chir Ital 49(3):9–13
Sasako M, Sano T, Katai H, Maruyama K (1997) Radical surgery. In: Sugimura T, Sasako M (eds) Gastric cancer. Oxford University Press, Oxford, England, pp 223–248
Sayegh M, Takeshi S, Simon D et al (2004a) Gastric cancer. Springer, Tokyo, pp 140–148
Sayegh ME, Sano T, Dexter S, Katai H, Fukagawa T, Sasako M (2004b) TNM and Japanese staging systems for gastric cancer: how do they coexist? Gastric Cancer 7(3):140–148
Schein PS, Novak J (1982) A comparison of combination chemotherapy and combined modality therapy for locally advanced gastric carcinoma. Cancer 49:1771
Schein PS, Macdonald JS, Hoth D, Woolley PV (1978) Mitomycin C, experience in the United States, with emphasis on gastric cancer. Recent Results Cancer Res 63:148–151
Siewert JR, Bottcher K, Roder JD et al; German Gastric Carcinoma Study Group (1993) Prognostic relevance of systematic lymph node dissection in gastric carcinoma. Br J Surg 80(8):1015–1018
Siewert JR, Kelsen D, Maruyama K, Feussner H, Omote K, Etter M et al (2000) Gastric cancer diagnosis and treatment – an interactive training program, 1st edn. Springer Electronic Media, Berlin, Germany
Skoropad VY, Berdov BA, Mardynski YS et al (2000) A prospective, randomized trial of preoperative and intraoperative radiotherapy versus surgery alone in resectable gastric cancer. Eur J Surg Oncol 26:773
Smalley SR, Gunderson LL (1996) Stomach. In: Perez CA, Brady LW (eds) Principles and practice of radiation oncology, 3rd edn. Lippincott-Raven Publishers, Philadelphia, PA
Stout AP (1943) Pathology of carcinoma of the stomach. Arch Surg 46:807
Sue-Ling HM, Johnston D, Martin IG et al (1993) Gastric cancer: a curable disease in Britain. BMJ 307(6904):591–596
Takahashi M, Abe M (1986) Intraoperative radiotherapy for carcinoma of the stomach. Eur J Surg Oncol 12:247
Tey J, Shakespeare TP, Mukherjee RK et al (2007) The role of palliative radiation therapy in symptomatic locally advanced gastric cancer. Int J Radiat Oncol Biol Phys 67:385
Thomson FB, Robins RE (1952) Local recurrence following subtotal resection for gastric carcinoma. Surg Gynecol Obstet 95:341
Uyama I, Ogiwara H, Takahara T, Kikuchi K, Iida S, Kubota T et al (1996) Spleen- and pancreas-preserving total gastrectomy with superextended lymphadenectomy including dissection of the para-aortic lymph nodes for gastric cancer. J Surg Oncol 63(4):268–270
van den Brandt P, Goldbohm R (2006) Nutrition in the prevention of gastrointestinal cancer. Best Pract Res Clin Gastroenterol 20(3):589–603
VanCutsen E, Kang Y, Chung L, Shen L, et al (2009) Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal groth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). ASCO:Abstract LBA4509
Vanhoefer U, Rougier P, Wilke H et al (2000) Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 18(14):2648–2657
Verschueren R, Willemse P, Sleijfer D et al (1988) Combined chemotherapeutic-surgical approach of locally advanced gastric cancer. Proc Am Soc Clin Oncol 7:93
Waters JS, Norman A, Cunningham D et al (1999) Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer 80(1–2):269–272
Wilke H, Preusser P, Fink U et al (1989) Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol 7:1318
Wilke H, Preusser P, Fink U et al (1990) High dose folinic acid/etoposide/5-fluorouracil in advanced gastric cancer – a phase II study in elderly patients or patients with cardiac risk. Invest New Drugs 8(1):65–70
Wotherspoon A, Doglioni C, Diss T et al (1993) Regression of primary low-grade Bcell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 342:575
Wu-Williams A, Yu M, Mack T (1990) Life-style, workplace, and stomach cancer by subsite in young men of Los Angeles County. Cancer Res 50:2569–2576
Yamamoto H, Sekine Y, Higashizawa T, Kihira K, Kaneko Y, Hosoya Y et al (2001) Successful en bloc resection of a large superficial gastric cancer by using sodium hyaluronate and electrocautery incision forceps. Gastrointest Endosc 54(5):629–632
Yano M, Shiozaki H, Inoue M et al (2002) Neoadjuvant chemotherapy followed by salvage surgery: effect on survival of patients with primary noncurative gastric cancer. World J Surg 26:1155
Yoshikane H, Sakakibara A, Hidano H, Niwa Y, Goto H, Yokoi T (2001) Piecemeal endoscopic aspiration mucosectomy for large superficial intramucosal tumors of the stomach. Endoscopy 33(9):795–799
Zhang Z-X, Gu X-Z, Yin W-B et al (1998) Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of the gastric cardia (AGC) – report on 370 patients. Int J Radiat Oncol Biol Phys 42:929
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Berlin Heidelberg
About this chapter
Cite this chapter
Macdonald, J.S., Hundahl, S., Smalley, S.R., O’Dea, D., Mitchell, E.P. (2011). Gastric Cancer. In: Blanke, C., Rödel, C., Talamonti, M. (eds) Gastrointestinal Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-13306-0_5
Download citation
DOI: https://doi.org/10.1007/978-3-642-13306-0_5
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-13305-3
Online ISBN: 978-3-642-13306-0
eBook Packages: MedicineMedicine (R0)